Related Experiment Video
Updated: Feb 20, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
New dimeric cGMP analogues reduce proliferation in three colon cancer cell lines
Dorit Hoffmann1, Andreas Rentsch2, Eleonora Vighi1
1Università degli Studi di Modena e Reggio Emilia, Via Campi 287, 41125 Modena, Italy.
Abstract:
Activation of the cGMP-dependent protein kinase G (PKG) can inhibit growth and/or induce apoptosis in colon cancer. In this study we evaluated the effects on cell viability, cell death and proliferation of novel dimeric cGMP analogues, compared to a monomeric compound. Three colon cancer cell lines, which only express isoform 2 of PKG, were treated with these novel cGMP analogues and responded with increased PKG activity. cGMP analogues reduced cell viability in the three cell lines and this was due to a cytostatic rather than cytotoxic effect. These findings suggest that activation of PKG2 can be a therapeutic target in the treatment of colon cancer and, most importantly, that dimeric cGMP analogues can further improve the beneficial effects previously observed with monomeric cGMP analogues.
Insights
Novel dimeric cyclic GMP (cGMP) analogues activate protein kinase G (PKG) to inhibit colon cancer cell growth. These dimeric compounds show enhanced therapeutic potential compared to monomeric versions for colon cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- cGMP-dependent protein kinase G (PKG) activation can inhibit colon cancer growth and induce apoptosis.
- PKG isoform 2 is the primary PKG expressed in the studied colon cancer cell lines.
Purpose of the Study:
- To evaluate the effects of novel dimeric cGMP analogues on colon cancer cell viability, cell death, and proliferation.
- To compare the efficacy of dimeric cGMP analogues against monomeric compounds.
- To investigate the therapeutic potential of PKG2 activation in colon cancer.
Main Methods:
- Treatment of three colon cancer cell lines with novel dimeric and monomeric cGMP analogues.
- Measurement of PKG activity, cell viability, cell death, and proliferation rates.
- Analysis of the cytostatic versus cytotoxic effects of the compounds.
Main Results:
- All three colon cancer cell lines showed increased PKG activity upon treatment with the novel cGMP analogues.
- cGMP analogues reduced cell viability in all tested cell lines.
- The reduction in cell viability was primarily a cytostatic effect, not cytotoxic.
Conclusions:
- Activation of PKG2 is a viable therapeutic target for colon cancer treatment.
- Dimeric cGMP analogues demonstrate improved efficacy over monomeric compounds.
- Novel dimeric cGMP analogues hold promise for enhancing colon cancer therapy.
